When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients
    Baldwin, David S.
    Tiwari, Nupur
    Gordon, Robert
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (23) : 3276 - 3279
  • [32] Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder
    Sabioni, Pamela
    Bertram, Jonathan
    Le Foll, Bernard
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (23) : 3306 - 3310
  • [33] Quality, Safety and Efficacy in the 'Off-Label' Use of Medicines
    Kairuz, Therese Eileen
    Gargiulo, Derryn
    Bunt, Craig
    Garg, Sanjay
    CURRENT DRUG SAFETY, 2007, 2 (01) : 89 - 95
  • [34] The knowledge and experience with the off-label use - results of a survey
    Drenska, Maria
    Naseva, Emilia
    Getov, Ilko
    PHARMACIA, 2019, 66 (04) : 217 - 221
  • [35] OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS
    Spina, Edoardo
    Fava, Giuseppina
    Makos, Xenofon
    CLINICAL NEUROPSYCHIATRY, 2009, 6 (01): : 11 - 20
  • [36] Off-label use of atypical antipsychotics in personality disorders
    Rosenbluth, Michael
    Sinyor, Mark
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (11) : 1575 - 1585
  • [37] Off-label and unlicensed use of antidotes in paediatric patients
    Lifshitz, M
    Gavrilov, V
    Gorodischer, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (11) : 839 - 841
  • [38] OFF-LABEL USE OF PSYCHOTROPIC MEDICATIONS: FOCUS ON ANTIDEPRESSANTS
    Marazziti, Donatella
    Golia, Francesca
    Carlini, Marina
    Botti, Francesco
    Dell'Osso, Liliana
    CLINICAL NEUROPSYCHIATRY, 2008, 5 (05): : 245 - 253
  • [39] Use of off-label drugs in neonatal intensive care
    Sucasas Alonso, Andrea
    Avila-Alvarez, Alejandro
    Combarro Eiriz, Marina
    Martinez Roca, Cristina
    Yanez Gomez, Pedro
    Codias Lopez, Alejandra
    Fernandez Trisac, Jose Luis
    Pertega Diaz, Sonia
    ANALES DE PEDIATRIA, 2019, 91 (04): : 237 - 243
  • [40] Off-label use of medicines in South Africa: a review
    Ngcobo, N. N.
    Mathibe, L. J.
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)